About dermata therapeutics inc - DRMA
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.
DRMA At a Glance
Dermata Therapeutics, Inc.
3525 Del Mar Heights Road
San Diego, California 92130
| Phone | 1-858-800-2543 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -12,287,461.00 | |
| Sector | Health Technology | Employees | 8 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
DRMA Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.177 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | 0.088 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | N/A |
DRMA Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,535,932.625 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DRMA Liquidity
| Current Ratio | 1.791 |
| Quick Ratio | 1.791 |
| Cash Ratio | 1.603 |
DRMA Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -213.463 |
| Return on Equity | -310.442 |
| Return on Total Capital | -787.106 |
| Return on Invested Capital | -310.442 |
DRMA Capital Structure
| Total Debt to Total Equity | N/A |
| Total Debt to Total Capital | N/A |
| Total Debt to Total Assets | N/A |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |